Birchview Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Birchview Capital’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-80,000	Closed	-$332K	–	48
2019 Q4	$332K	Hold	80,000	–	–	0.24%	42
2019 Q3	$241K	Hold	80,000	–	–	0.16%	40
2019 Q2	$503K	Hold	80,000	–	–	0.31%	32
2019 Q1	$445K	Buy	80,000 +60,000	+300%	+$364K	0.28%	31
2018 Q4	$133K	Buy	+20,000	New	+$162K	0.13%	44

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Birchview Capital's LXRX Position: Q1 2020 in Review

Birchview Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2020, closing a stake of 80,000 shares — an estimated $332K sold.

Birchview Capital first reported a position in LXRX in Q4 2018 and held it in 5 quarters. The position peaked at $503K in Q2 2019. 113 funds tracked by Wall St. Rank hold LXRX as of Q1 2020.

Birchview Capital reported no remaining Lexicon Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Birchview Capital sold 80,000 Lexicon Pharmaceuticals shares in Q1 2020, an estimated $332K.
Birchview Capital first reported a position in Lexicon Pharmaceuticals in Q4 2018 and held it in 5 quarters.
Birchview Capital's Lexicon Pharmaceuticals position peaked at $503K in Q2 2019.
113 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2020.

Based on Birchview Capital's 13F filing for Q1 2020, filed 12 May 2020.